Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

For reasons that remain unclear, kidney cancer risk was higher in users of GLP-1 agonists, particularly those under 65 and those who were overweight versus obese.< Patients taking GLP-1 agonists for ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Everyone is allowed to have their own opinion. But it’s important for me to own my own narrative and tell my own story.” ...

At a time when shedding pounds may be just a shot away, WeightWatchers is returning to its roots and its community to chart a ...

As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one ...

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...